JP2022554230A - 神経系の状態の処置 - Google Patents

神経系の状態の処置 Download PDF

Info

Publication number
JP2022554230A
JP2022554230A JP2022524568A JP2022524568A JP2022554230A JP 2022554230 A JP2022554230 A JP 2022554230A JP 2022524568 A JP2022524568 A JP 2022524568A JP 2022524568 A JP2022524568 A JP 2022524568A JP 2022554230 A JP2022554230 A JP 2022554230A
Authority
JP
Japan
Prior art keywords
methylumbelliferone
use according
derivatives
pnni
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554230A5 (https=
Inventor
クウォク ジェシカ
フォスター リチャード
ダンカン ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2022554230A publication Critical patent/JP2022554230A/ja
Publication of JP2022554230A5 publication Critical patent/JP2022554230A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022524568A 2019-10-25 2020-10-25 神経系の状態の処置 Pending JP2022554230A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926001P 2019-10-25 2019-10-25
US62/926,001 2019-10-25
PCT/EP2020/079979 WO2021078991A1 (en) 2019-10-25 2020-10-25 Treatment of conditions of the nervous system

Publications (2)

Publication Number Publication Date
JP2022554230A true JP2022554230A (ja) 2022-12-28
JP2022554230A5 JP2022554230A5 (https=) 2023-11-06

Family

ID=73455660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524568A Pending JP2022554230A (ja) 2019-10-25 2020-10-25 神経系の状態の処置

Country Status (5)

Country Link
US (1) US20220380331A1 (https=)
EP (1) EP4048257A1 (https=)
JP (1) JP2022554230A (https=)
CN (1) CN115023222A (https=)
WO (1) WO2021078991A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099818A1 (en) * 2021-11-30 2023-06-08 Evexys Biotech Oy Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (pcpev)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514438A (ja) * 1998-05-08 2002-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チトクロームｐ４５０基質としての７−アルコキシクマリン類
JP2008535824A (ja) * 2005-03-29 2008-09-04 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換アミノアルキルベンゾピラン誘導体およびアミドアルキルベンゾピラン誘導体
JP2016530265A (ja) * 2013-08-12 2016-09-29 ベナロヤ リサーチ インスティテュート アット バージニア メイソン 免疫調節のための４−メチルウンベリフェロン処置
US20180201640A1 (en) * 2017-01-13 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103446154A (zh) * 2012-05-29 2013-12-18 中国医学科学院药物研究所 香豆素衍生物在防治脑部重大疾病中的应用
US11278518B2 (en) * 2017-01-13 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514438A (ja) * 1998-05-08 2002-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チトクロームｐ４５０基質としての７−アルコキシクマリン類
JP2008535824A (ja) * 2005-03-29 2008-09-04 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換アミノアルキルベンゾピラン誘導体およびアミドアルキルベンゾピラン誘導体
JP2016530265A (ja) * 2013-08-12 2016-09-29 ベナロヤ リサーチ インスティテュート アット バージニア メイソン 免疫調節のための４−メチルウンベリフェロン処置
US20180201640A1 (en) * 2017-01-13 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARCH. PHARM. CHEM. LIFE SCI., vol. 350, JPN6024040500, 2017, pages 1700076 - 1, ISSN: 0005645636 *
BR. J. PHARMACOL., vol. 176(18), JPN6024040498, September 2019 (2019-09-01), pages 3611 - 3621, ISSN: 0005645635 *
CHEM. MED. CHEM., vol. 12(16), JPN6024040496, 2017, pages 1349 - 1358, ISSN: 0005645634 *
CHEMISTRYSELECT, vol. 1, JPN6024040499, 2016, pages 2742 - 2749, ISSN: 0005645637 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 161, JPN6024040497, October 2018 (2018-10-01), pages 292 - 309, ISSN: 0005645638 *

Also Published As

Publication number Publication date
WO2021078991A1 (en) 2021-04-29
EP4048257A1 (en) 2022-08-31
CN115023222A (zh) 2022-09-06
US20220380331A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
DE69732049T2 (de) Pharmazeutische zubereitungen, enthaltend salze von hyaluronsäure und lokalanästhetika
KR20030076604A (ko) 이질통 또는 그밖의 다른 상이한 형태의 만성 또는 환각통증을 치료하기 위한 펩타이드 부류의 화합물의 신규한용도
SK287539B6 (sk) Použitie peptidovej zlúčeniny na prípravu farmaceutického prostriedku na liečenie bolesti
Fan et al. Paeoniflorin attenuates postoperative pain by suppressing matrix metalloproteinase‐9/2 in mice
Sharif Neuropathology and therapeutics addressing glaucoma, a prevalent retina-optic nerve-brain disease that causes eyesight impairment and blindness
CN1310622A (zh) 丙戊酸类似物在治疗和预防偏头痛与情感性疾病中的应用
EP3965769B1 (en) Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
JP2022554230A (ja) 神経系の状態の処置
US20090263507A1 (en) Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
US20250345350A1 (en) Treating pain associated with central sensitization
Tanridag et al. Motor neuron degeneration due to aluminium deposition in the spinal cord: a light microscopical study
Pan et al. Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats
CN121818623A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗癫痫持续状态
Masegosa et al. ICA-27243 improves neuromuscular function and preserves motoneurons in the transgenic SOD1G93A mice
Li et al. Acid-sensing ion channel 3 expression is increased in dorsal root ganglion, hippocampus and hypothalamus in remifentanil-induced hyperalgesia in rats
US9192602B2 (en) Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain
EP3362059B1 (en) New combination therapies for treating neurological damage
EP4093395B1 (en) Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
US11992469B2 (en) Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury
Zhang et al. MaR1 and NGF combine to inhibit autophagy through the GSK-3β/β-catenin pathway to promote sciatic nerve repair
Korimová et al. Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat
EP4699605A1 (en) Use of novel compound for treating intractable diseases
US20080058260A1 (en) Reversible inhibition of pyramidal gap junction activity
WO2017015774A1 (es) Metodo para el tratamiento del dolor mediante la intervencion de panexinas espinales
HK40100168A (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421